Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 and DLI Post-Transplant for High-Risk MDS/AML
NCT04857645Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Jun 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of inqovi in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Groupe Français des Myélodysplasies. Started Jun 2021; status: completed.
02
Drugs
inqovi
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04857645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857645.